Small, Dense LDL Particles Predict Changes in Intima Media Thickness and Insulin Resistance in Men with Type 2 Diabetes and Prediabetes - A Prospective Cohort Study by Gerber, Philipp A et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Small, Dense LDL Particles Predict Changes in Intima Media Thickness and
Insulin Resistance in Men with Type 2 Diabetes and Prediabetes - A
Prospective Cohort Study
Gerber, Philipp A; Thalhammer, Christoph; Schmied, Christian; Spring, Silviana; Amann-Vesti,
Beatrice; Spinas, Giatgen A; Berneis, Kaspar
Abstract: The association of small, dense low-density lipoprotein (sdLDL) particles with an increased
cardiovascular risk is well established. However, its predictive value with regard to glucose metabolism
and arterial disease in patients with type 2 diabetes has not been thoroughly investigated. We conducted
a prospective longitudinal cohort study in patients with (pre)diabetes who were seen at baseline and
after two years. sdLDL particles were determined by gradient gel electrophoresis. Insulin resistance was
estimated by using the homeostatic model assessment 2 (HOMA2). Intima media thickness (IMT) and
flow-mediated dilation (FMD) were assessed by ultrasound measurements. Fifty-nine patients (mean age
63.0 ± 12.2 years) were enrolled and 39 were seen at follow-up. IMT increased in the whole cohort during
follow-up. The change in IMT was predicted by the proportion of sdLDL particles at baseline (p=0.03),
and the change in FMD was predicted by LDL-cholesterol levels at baseline (p=0.049). HOMA2 and
changes in HOMA2 correlated with the proportion of sdLDL particles and changes in this proportion,
respectively (p<0.05 for both). Serum resistin levels increased in parallel with the increasing sdLDL
particle number, while serum adiponectin increased only in patients with unaltered sdLDL particle num-
ber at follow-up (p<0.01 for both). In conclusion, the proportion of small, dense LDL particles and
changes in this proportion are predictive of changes in intima media thickness and insulin resistance,
and are closely associated with other determinants of an adverse metabolic status. Thus, this parameter
extends the individual risk assessment beyond the limitations of traditional risk markers in patients with
dysglycemia.
DOI: 10.1371/journal.pone.0072763
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-81352
Published Version
Originally published at:
Gerber, Philipp A; Thalhammer, Christoph; Schmied, Christian; Spring, Silviana; Amann-Vesti, Beatrice;
Spinas, Giatgen A; Berneis, Kaspar (2013). Small, Dense LDL Particles Predict Changes in Intima Media
Thickness and Insulin Resistance in Men with Type 2 Diabetes and Prediabetes - A Prospective Cohort
Study. PLoS ONE, 8(8):e72763. DOI: 10.1371/journal.pone.0072763
Small, Dense LDL Particles Predict Changes in Intima
Media Thickness and Insulin Resistance in Men with Type
2 Diabetes and Prediabetes – A Prospective Cohort Study
Philipp A. Gerber1,4*, Christoph Thalhammer2, Christian Schmied3, Silviana Spring2, Beatrice Amann-
Vesti2, Giatgen A. Spinas1,4, Kaspar Berneis1,5
1 Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital, Zürich, Zurich, Switzerland, 2 Division of Angiology, University Hospital, Zürich,
Zurich, Switzerland, 3 Division of Cardiology, University Hospital, Zürich, Zurich, Switzerland, 4 Competence Centre for Systems Physiology and Metabolic
Diseases, Zürich, Switzerland, 5 Centre for Integrative Human Physiology, Zürich, Switzerland
Abstract
The association of small, dense low-density lipoprotein (sdLDL) particles with an increased cardiovascular risk is well
established. However, its predictive value with regard to glucose metabolism and arterial disease in patients with type
2 diabetes has not been thoroughly investigated. We conducted a prospective longitudinal cohort study in patients
with (pre)diabetes who were seen at baseline and after two years. sdLDL particles were determined by gradient gel
electrophoresis. Insulin resistance was estimated by using the homeostatic model assessment 2 (HOMA2). Intima
media thickness (IMT) and flow-mediated dilation (FMD) were assessed by ultrasound measurements. Fifty-nine
patients (mean age 63.0 ± 12.2 years) were enrolled and 39 were seen at follow-up. IMT increased in the whole
cohort during follow-up. The change in IMT was predicted by the proportion of sdLDL particles at baseline (p=0.03),
and the change in FMD was predicted by LDL-cholesterol levels at baseline (p=0.049). HOMA2 and changes in
HOMA2 correlated with the proportion of sdLDL particles and changes in this proportion, respectively (p<0.05 for
both). Serum resistin levels increased in parallel with the increasing sdLDL particle number, while serum adiponectin
increased only in patients with unaltered sdLDL particle number at follow-up (p<0.01 for both). In conclusion, the
proportion of small, dense LDL particles and changes in this proportion are predictive of changes in intima media
thickness and insulin resistance, and are closely associated with other determinants of an adverse metabolic status.
Thus, this parameter extends the individual risk assessment beyond the limitations of traditional risk markers in
patients with dysglycemia.
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Introduction
The risk of cardiovascular events in individuals with impaired
glucose metabolism is similar to patients with a history of a
prior cardiovascular event [1] and dysglycemia is associated
with parameters of vascular damage [2]. However, increasing
hyperglycemia in type 2 diabetes does not contribute to the
cardiovascular risk to the same extent as it does in type 1
diabetes [3], pointing to the importance of nonglycemic related
risk factors belonging to the “metabolic syndrome”. Numerous
studies could demonstrate an increased cardiovascular risk in
patients with metabolic syndrome prior to the development of
overt hyperglycemia [4,5]. Likewise, patients with type 2
diabetes or metabolic syndrome have an increased
cardiovascular risk despite optimal control of other risk factors
as low-density lipoprotein cholesterol (LDL-C) [6].
In the context of the shortcomings of commonly assessed
risk factors in individuals with features of the metabolic
syndrome, the characterization and subclassification of LDL
particles emerged as a tool that may offer a better risk
prediction. An increase in sdLDL (small, dense LDL particles,
class III and IV) is closely associated with an increased
cardiovascular risk, independently of the traditional risk factors
both in patients with [7–9] and without [10–12] diabetes or
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e72763
metabolic syndrome. Individual LDL particle profiles normally
cluster into two patterns of LDL size distribution: The majority
of profiles demonstrates a predominance of large or medium
sized LDL particles (LDL pattern A), whereas a substantial
minority exhibits the LDL pattern B with a higher proportion of
smaller LDL particles [13].
Several aspects contribute to the significance of sdLDL in
patients with the metabolic syndrome. The formation of sdLDL
particles seems to be favoured in the presence of insulin
resistance and hypertriglyceridemia [14,15]. Furthermore, there
is growing evidence that sdLDL not only are more susceptible
to oxidative modification [16], but also more prone to glycation
[17] which further aggravates their atherogenicity in a
hyperglycemic environment.
In several studies the association of sdLDL with actual
insulin resistance and cardiovascular risk factors has been
tested in a cross-sectional manner in patients with disturbed
glucose metabolism; however, there is not much data about the
longitudinal predictive value of these particles. Therefore, this
study was designed to assess the relationship between sdLDL
and parameters associated with insulin resistance and the
metabolic syndrome including markers for atherosclerosis
during a long-term follow-up in this population.
Materials and Methods
Study protocol
A cohort of 59 patients consulting the outpatient clinic of the
Division of Endocrinology, Diabetes and Clinical Nutrition or the
Division of Cardiology of the University Hospital, Zurich were
included in a prospective study. In order to avoid gender
related differences in outcome, the study was restricted to male
patients. After written informed consent was given, subjects
underwent physical examination and blood tests, and were
asked to fill in a questionnaire on personal and medical data,
including age, past medical history and current medication. The
adopted procedures were in agreement with the Helsinki
Declaration of 1975, as revised in 1983. The study was
approved by the Ethics Committee of the Canton of Zürich,
Switzerland and registered at clinicaltrials.gov (NCT01584856).
Inclusion criteria were male gender, impaired fasting glucose
or type 2 diabetes according to the ADA criteria [18] and BMI
>25 kg/m2 as well as given informed consent. Exclusion criteria
were HbA1c >9.0%, insulin therapy, fasting glucose >11mmol/l,
total cholesterol >6.5 mmol/l or fasting triglycerides >2.5
mmol/l, malignant or severe renal, hepatic, pulmonary,
neurological or psychiatric disease, alcohol or drug abuse and
HIV infection.
After inclusion, patients were seen for a first visit within a few
weeks and after two years they were invited for the follow-up
visit.
Medical history and anthropometric measurements
Body weight was measured to the nearest 100 gram, height
to the nearest centimetre. BMI (body mass index) was
calculated as weight/height2 (kg/m2). Blood pressure was
measured with a mercury sphingomanometer after 5 minutes in
the sitting position.
The presence of macrovascular comorbidities was defined
as past myocardial infarction or cardiac intervention
(percutaneous intervention or bypass surgery), history of
cerebral ischemia (transient ischemic attack, stroke) or
peripheral arterial disease (ABI <0.90 or percutaneous
intervention or peripheral bypass surgery).
Biochemical analyses
A blood sample was taken at both visits after 12-14 hours of
overnight fast in sodium-EDTA tubes and stored at -80 °C.
Patients were asked to omit antidiabetic treatment on the
evening before their visit. Blood glucose before and after a
standard oral glucose (75g) tolerance test was directly
measured from whole-blood samples from a finger stick
(fasting, 1-h and 2-h samples) by using plasma referenced
reflection photometry (Reflotron Sprint; Roche, Basel,
Switzerland). Insulin resistance was estimated from fasting
glucose and C-peptide concentrations by using a computer-
based homeostasis model assessment system (HOMA2-IR)
provided by the Oxford Centre for Diabetes, Endocrinology,
and Metabolism (http://www.dtu.ox.ac.uk/homa).
HbA1c was measured with the DCA 2000 (Bayer
Diagnostics, Elkhart, USA) according to the manufacturer’s
instructions. Measurement of urinary albumin and creatinine
was done in spot urine with the DCA 2000. Microalbuminuria
was defined as presence of urinary albumin/creatinine ratio
>2.5 mg/mmol, macroalbuminuria was defined as presence of
an urinary albumin/creatinine ratio >25 mg/mmol [19].
Cholesterol was measured by an enzymatic colorimetric test
using cholesterol esterase and cholesterol oxidase,
triglycerides were determined by a colorimetric reaction with
iodonitrotetrazolium chloride after enzymatic hydrolysis
(modular P lab analyzer, Roche, Switzerland). HDL
measurement was done by a homogeneous enzymatic test
(Cobas Integra lab analyzer, Roche, Switzerland). LDL was
calculated with the Friedewald formula [20].
Nondenaturing polyacrylamide GGE (gradient gel
electrophoresis) of plasma was performed at 10-14 °C in
2-16% polyacrylamide gradient gels. Gels were subjected to
electrophoresis for 24 h at 125 V in tris borate buffer (pH 8.3)
as described elsewhere [21]. Gels were fixed and stained for
lipids in a solution containing Oil Red O in 60% ethanol at 55
°C. Gels were placed on a light source and photographed using
a Luminescent Image Analyzer, LAS-3000 of Fujifilm. Migration
distance for each absorbance peak was determined and the
molecular diameter corresponding to each peak was calculated
from a calibration curve generated from the migration distance
of size standards of known diameter, which includes
carboxylated latex beads (Duke Scientific, Palo Alto, CA),
thyroglobulin and apoferritin (HMW Std, Pharmacia,
Piscataway, NJ) having molecular diameter of 380 nm, 170 nm
and 122 nm, respectively, and lipoprotein calibrators of
previously determined particle size. LDL subclass distribution
(LDL I, IIA, IIB, IIIA, IIIB, IVA and IVB) as percentage of total
LDL was calculated as previously described [21].
From frozen serum, C-peptide was measured by using
radioimmunoassay (RIA) (IRMA-C-PEP; CIS Bio International,
Bagnols-sur-Cèze Cedex, France), adiponectin and resistin
Small, Dense LDL Predict Disease in Diabetes
PLOS ONE | www.plosone.org 2 August 2013 | Volume 8 | Issue 8 | e72763
were measured by using ELISA (DRP300 and DRSN00 ELISA
Kits; R&D Systems, Minneapolis, MN).
Vascular assessment
IMT (Intima media thickness) was measured in both common
carotid arteries using high-resolution B-mode ultrasound with a
9-3 MHz linear array transducer (iU22, Philips, Best,
Netherlands) as previously described [22,23]. Reference point
for the measurements of IMT was 1 to 2 cm proximal to the
dilatation of the carotid bulb. The far wall was scanned from an
anterolateral direction and IMT was automatically computed by
the ultrasound software (QLAB, Philips, Best, Netherlands).
Mean IMT was calculated as the mean of both common carotid
arteries.
Forearm blood flow of the brachial artery is increased in
response to transient hyperaemia and was studied using high-
resolution ultrasound of the brachial artery [24,25]. Patients
were lying in supine position for 10 minutes at rest before the
measurement was started. The right arm was fixed in
extended, relaxed position to allow correct analysis of the
brachial artery 2-5 cm above the antecubital fossa. The
brachial artery was visualized longitudinally using a 17-5 MHz
linear array ultrasound transducer (iU22, Philips, Best,
Netherlands); B-mode and pulsed Doppler spectral curve were
recorded. A cuff placed around the forearm distal to the imaged
artery segment was inflated to about 30 mmHg of above the
systemic systolic arterial pressure for five minutes. Maximal
brachial artery diameter was determined and the mean value of
vessel calibre was calculated from six single measurements
made before the cuff inflation and from six records taken every
minute after cuff release. The peak value diameter acquired
during ischemia-induced hyperaemia was used for the
evaluation of the percentage FMD (flow mediated
vasodilatation) (maximum diameter - baseline diameter) /
baseline diameter x 100%.
Statistical analyses
Data are expressed as arithmetic means ± SDs for normally
distributed variables and as geometric means ± SDs for non-
normally distributed data. For the analysis of independent
categorical frequency data, the χ2 test was applied, and for
related categorical frequency data, a McNemar test was
performed. For comparison of continuous variables in two
independent groups, the Mann–Whitney test was used, for
related samples, the Wilcoxon test was applied (Multiple).
linear regression was used for the testing of correlations. A
value of p < 0.05 was considered significant. Outliers were only
excluded if identified by both the Dixon’s and the Grubbs’ test
with high significance (p<0.01). The statistical analyses were
performed using SPSS 20 software (IBM, New York, USA) for
Windows (Microsoft, Redmond, USA).
Results
Demographic characteristics
Fifty-nine white males were included in the study and
assessed for baseline characteristics, 39 (66%) of them were
seen again for a second assessment; the 20 remaining
subjects were excluded because they refused further
participation after the first assessment (5 subjects) or they had
to be excluded due to the study’s exclusion criteria (low BMI 4,
high triglycerides 4, high creatinine 4, insulin therapy 2,
malignant disease 1). The mean time between the first and the
second assessment was 24.9 ± 1.2 months. Baseline
anthropometric and biochemical data of all patients are
summarized in Table 1. 34% of all participants were known to
have peripheral arterial disease, 19% had a history of
myocardial infarction and 4% had a history of stroke. Diabetic
retinopathy was known in 5% of participants and diabetic
neuropathy in 18%. Nephropathy as assessed by
microalbuminuria (albumin/creatinine ratio) at baseline was
present in 32%. 73% of study participants received oral
antidiabetic drugs, with metformin being the mostly prescribed
substance (in 77% of treated participants). 59% of the patients
were treated with a statin.
Assessment of LDL particle size
Analysis of LDL particle size by GGE revealed a mean
particle size of 262.4 ± 8.5 nm, with 25.4% of the subjects
exhibiting a pattern B phenotype. The proportion of small
dense LDL particles (class III/IV) was 39.0 ± 11.2% at baseline
and 43.6 ± 11.5% at follow up. In 68% of patients, this
proportion had increased during follow-up. Patients with known
previous myocardial infarction had a significantly higher
proportion of sdLDL particles at baseline (49.8% vs. 37.5% in
patients without history of myocardial infarction, p=0.007). With
regard to mean LDL particle size and distibution there was no
difference at baseline and at follow-up when study participants
treated with statin therapy were compared with those who had
no lipid lowering therapy. In contrast, LDL concentration was
significantly lower in treated patients at baseline (2.1 ± 0.9
mmol/l vs. untreated 2.9 ± 0.7 mmol/l, p<0.001) and after
follow-up (2.1 ± 1.0 mmol/l vs. untreated 2.9 ± 1.0 mmol/l,
p=0.005). There was no association of changes in BMI with
changes in sdLDL particles during follow-up.
Table 1. Baseline characteristics of study participants.
Characteristic Baseline
Age (y) 63.0 ± 12.2
Duration of diabetes or prediabetes (y) 7.3 ± 7.0
BMI (kg/m2) 30.5 ± 6.5
Waist-to-Hip Ratio 1.01 ± 0.05
Systolic blood Pressure (mmHg) 137.3 ± 16.6
Diastolic blood pressure (mmHg) 78.6 ± 8.5
Total Cholesterol (mmol/l) 4.4 ± 1.0
HDL Cholesterol (mmol/l) 1.2 ± 0.4
Triglycerides (mmol/l) 1.8 ± 1.0
LDL Cholesterol (mmol/l) 2.4 ± 0.9
Mean ± standard deviation
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LDL particle size distribution and measures of arterial
disease
Intima-media thickness (IMT) and flow mediated dilation
(FMD) were assessed as surrogate markers to detect
morphological and functional changes of the arterial system.
IMT was 0.68 ± 0.14mm at baseline and was significantly
larger at the second assessment (0.73 ± 0.10mm, p=0.01).
FMD, which was 7.2 ± 5.3% at baseline, was 5.7 ± 4.5% after 2
years (ns). The change in IMT correlated with the proportion of
sdLDL particles at baseline (R2=0.124, p=0.03, Figure 1a).
Analysis using multiple linear regression revealed that small
dense LDL particles remained a predictor of IMT progression
even when including HbA1c, BMI, age and systolic blood
pressure into the model (p=0.003, table 2). In this analysis,
HbA1c, BMI and systolic blood pressure did not correlate with
IMT progression, however a higher age (which correlated with
higher IMT at baseline, p=0.004) predicted less IMT
progression (table 2). Furthermore, none of the traditional lipid
parameters (Total and LDL-cholesterol, HDL-cholesterol,
triglycerides) at baseline was associated with changes in IMT.
Deterioration of FMD during follow-up was predicted by the
level of LDL-cholesterol at baseline (R2=0.103, p=0.049, Figure
1b) but not the proportion of sdLDL particles, other
conventional lipid parameters or age, HbA1c or BMI. High
systolic or diastolic blood pressure was not a predictor for a
reduced FMD, however, increasing systolic blood pressure
during the 2 years of follow-up was associated with worsening
of FMD (R2=0.102, p=0.05).
LDL particle size distribution and insulin resistance
Insulin resistance and glucose control were assessed by
measuring fasting glucose and HbA1c levels as well as on the
basis of a glucose tolerance test and HOMA2 calculations.
Measurements at the first and second visit are given in Table 3.
HbA1c significantly increased between the first and the second
assessment by 0.3 ± 0.7% (p=0.03). At baseline, C-Peptide
concentration and insulin resistance both correlated with the
proportion of sdLDL particles (p=0.02 and p=0.04,
respectively). The association of HOMA2 estimated insulin
resistance with sdLDL particles was still present at the second
visit (p=0.02). Importantly, there was neither an association of
HOMA2 with HbA1c at baseline nor at follow-up. There was no
worsened insulin resistance in any of the patients in whom the
proportion of sdLDL particles did not rise during follow-up,
however, worsened insulin resistance occurred in 70.6% of
participants displaying an increased proportion of small, dense
LDL particles at follow-up (Figure 2a, p = 0.04). In contrast,
there was no relationship between worsening of glycemic
control (increase in HbA1c) and increased small LDL particles
(HbA1c +0.2 ± 0.8 vs. +0.4 ± 0.6 in patients without increased
sdLDL proportion, ns). Accordingly, there was no association
between changes in HbA1c and insulin resistance (HbA1c +0.2
± 0.5 vs. -0.2 ± 0.5 in patients with and without increase in
HOMA2, respectively, ns).
Regarding conventional lipid parameters, HDL-cholesterol
also correlated with HOMA2 estimated insulin resistance at
baseline and after 2 years (p=0.005 and p=0.004, respectively)
whereas triglyceride levels and the triglyceride/HDL-C ratio
only correlated with HOMA2 at baseline (p=0.02 and p=0.001,
respectively), but not after follow-up. Changes in HOMA2
during follow-up were not different between patients with
increased or stable HDL-cholesterol, triglyceride or triglyceride/
HDL-C ratio.
LDL particle size distribution and levels of adiponectin /
resistin
Serum levels of adiponectin and resistin were assessed at
both visits (table 3). In the whole cohort, resistin levels
increased (p=0.001) and were closely correlated with the
number of sdLDL particles at the first (p=0.02) and second
(p<0.001) visit. In patients showing an increase in the
proportion of sdLDL particles, resistin concentrations also
increased (p<0.001), which was not the case in those patients
whose sdLDL particle number did not rise during follow-up
(Figure 2b); the increase in resistin directly correlated with the
increase in sdLDL particle number (R2=0.149, p=0.01). On the
other hand, serum adiponectin increased only in patients
without increasing sdLDL particles (p=0.006), but not in those
with more sdLDL particles at follow-up. To assess relevant
effects of possible subclinical inflammation on resistin levels,
measures of C-reactive protein (CRP) were included in the
analysis in a subset of 16 patients at the first and / or second
visit. Resistin levels still correlated with sdLDL particles
(p=0.03), but not with logCRP levels (p=0.55) when this
parameter was included using multiple linear regression.
Table 2. Multiple linear regression was performed to assess
the correlation of changes in IMT with baseline
measurements of sdLDL particles, age, BMI, systolic blood
pressure and HbA1c.
  95% Confidence Interval  
Parameter Coefficient Lower Upper p-Value
sdLDL particles 0.004 0.001 0.006 0.003
Age -0.002 -0.004 0.000 0.04
BMI -0.004 -0.008 0.000 0.08
Systolic blood pressure 0.000 -0.002 0.001 0.74
HbA1c 0.016 -0.028 0.061 0.47
Table 3. Measures of glucose control, insulin resistance
and adipokines in patients attending both visits.
Characteristic Baseline Follow-up
Fasting glucose (mmol/l) 6.6 ± 1.3 6.9 ± 1.6
Glucose 60min after 75g oral glucose (mmol/l) 13.4 ± 3.0 12.3 ± 3.5
Glucose 120min after 75g oral glucose (mmol/l) 12.5 ± 4.2 10.6 ± 3.8
HbA1c (%) 6.4 ± 0.6 6.6 ± 0.9*
C-Peptide (nmol/l) 1.46 ± 0.77 1.69 ± 0.81
HOMA2-IR 3.36 ± 1.68 4.01 ± 1.88
Adiponectin (μg/ml) 4.98 ± 3.67 5.25 ± 3.58
Resistin (ng/ml) 15.4 ± 7.5 23.1 ± 16.4*
Mean ± standard deviation. * Significantly different from baseline, p<0.05
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No deaths and only one major cardiovascular event (stroke)
occurred during follow-up.
Discussion
This prospective cohort study demonstrates the value of LDL
particle size measurements in the prediction of changes in
metabolic status and cardiovascular disease in patients with
diabetes or prediabetes.
The fraction of small LDL particles at baseline predicted
changes in intima-media thickness that occurred during the
following two years, with a larger fraction of sdLDL particles
being associated with a larger increase in IMT. Whereas a
correlation of IMT with actual LDL particle size was
demonstrated by many earlier studies including our own data
[7,26], the predictive value of LDL size with regard to IMT in
dysglycemic patients has not been investigated in prospective
long-term studies. Of interest, other parameters as HbA1c,
BMI, or systolic blood pressure were not associated with the
extent of IMT increase in the present study. This might be
partly due to the inclusion criteria of the study, which narrowed
the spread of these parameters within the cohort and thereby
limited the possibility to determine their predictive value.
Further, the superiority of LDL particle size in comparison to
other conventional risk factors may also be due to its
comprehensive character – as the number of small LDL
Figure 1.  Prediction of changes in IMT and FMD bei sdLDL and LDL-C.  Changes in IMT during the 2 year follow-up are shown
in relation to the proportion of small, dense LDL particles at baseline (a). Changes in FMD during follow-up are shown in relation to
the proportion of LDL-C levels at baseline (1B), p<0.05.
doi: 10.1371/journal.pone.0072763.g001
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particles is influenced by age, weight, body composition and
also metabolic control and may therefore provide more precise
information. Higher age at baseline predicted less IMT
progression during follow-up, this is most probably because of
an association of higher age with an already significantly higher
IMT at baseline.
Of interest, changes in flow mediated dilation were only
predicted by the LDL-C concentration, but neither by sdLDL
levels or other lipid parameters nor by age, BMI or HbA1c,
whereas changes in IMT were only predicted by the proportion
of sdLDL particles, but not by LDL-C levels. It is, thus, tempting
to assume that changes in the arterial structure (as IMT) are
best predicted by a factor that robustly reflects the organism’s
cardiovascular risk status, whereas factors that are easily
modifiable (mostly by therapeutic interventions) are more likely
to predict functional characteristics (as FMD).
HbA1c levels provide insufficient information on
cardiovascular risk in patients with diabetes or prediabetes,
and this is reflected by the complete lack of an association of
this parameter with insulin resistance or changes in insulin
resistance in this study. HbA1c adequately reflects glycemia
and metabolic control achieved by antihyperglycemic therapy
and may predict a large proportion of the cardiovascular risk in
patients with type 1 diabetes, where hyperglycemia is the
predominant mediator of cardiovascular damage. However,
additional effects mediated by insulin resistance (e.g. altered
lipid metabolism) are not reflected by HbA1c. In contrast, in
addition to the direct association of absolute HOMA2 values
with sdLDL particles at the first and second visit (confirming our
previous cross-sectional data in another study population [15]),
changes in insulin resistance also differed clearly between
patients with and without an increase in sdLDL particles
between the two visits. While triglyceride and HDL-C
concentration as well as their ratio were also associated with
insulin resistance as previously established [27,28], changes of
HOMA2 were independent of changes in HDL-C or triglyceride
levels. Thus, alterations in the proportion of sdLDL particles
seem to be a very early and accurate predictor of alterations in
insulin resistance.
These observations are supported by concordant data on
serum adiponectin and resistin concentrations. Decreased
levels of adiponectin are known to be a reliable predictor of
insulin resistance and progression to type 2 diabetes [29,30]. In
this study, patients with stable or decreasing sdLDL number
showed a rise in adiponectin concentration during follow-up,
whereas adiponectin levels did not change if sdLDL particles
increased. Furthermore, a tight correlation of resistin levels with
the proportion of sdLDL particles could be observed at both
visits. Resistin concentration increased only in subjects who
also displayed an increase in sdLDL particles, with a direct
Figure 2.  Changes in HOMA2 and resistin / adiponectin levels depend on changes in the proportion of sdLDL
particles.  The Proportion of patients (%) with constant or improved insulin resistance (white) or worsened insulin resistance (black)
(assessed by HOMA2 during 2 years of follow-up) is shown for those patients with and those without an increase in small, dense
LDL particles (2A, p<0.05). Changes (%) of resistin and adiponectin levels during the 2 years of follow-up are shown in in patients
with and those without an increase in small, dense LDL particles (2B). * Significantly different from baseline, p<0.05.
doi: 10.1371/journal.pone.0072763.g002
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correlation of the increase in sdLDL particles and resistin
levels. Although the discussion about metabolic effects of
resistin in humans remains controversial, its association with
parameters of the metabolic syndrome has been repeatedly
documented [31,32]. Taken together, the concomitant changes
in adiponectin and resistin concentration strengthen the
argument for a predictive value of changes in the proportion of
small dense LDL particles concerning the metabolic status of
adipose tissue, which is one of the most important
determinants of the further course of insulin resistance and the
associated cardiovascular risk.
The strength of this study is its prospective longitudinal
character that allowed assessing the predictive value of small
dense LDL particles in a well defined cohort of male patients
with diabetes and prediabetes. Further, due to the single centre
design of the study, it was possible that all clinical and
biochemical assessments were performed at the same place
and by the same investigators, therefore limiting possible inter-
observer biases. This was of particular importance with respect
to the measurements of intima media thickness and flow-
mediated dilation. A limitation is the relatively small sample
size. Further, standardization of therapeutic interventions
regarding hyperglycemia and hypercholesterolemia were not
part of the study protocol, and therefore established glucose-
and cholesterol-lowering therapies may have influenced study
measures. However, glucose lowering treatment was
suspended the night before the visits. Furthermore, sdLDL
particle size distribution was assessed separately in patients
with and without statin therapy, without detectable differences.
In conclusion, this study provides evidence that the
proportion of small, dense LDL particles and changes in this
proportion predict changes in intima media thickness and
insulin resistance, and are closely associated with other
determinants of an adverse metabolic status. Therefore, this
parameter offers the possibility to extend the individual risk
assessment beyond the limitations of traditional risk markers in
patients with dysglycemia.
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